CoChat
Sign Up
Cited by 221

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study

Nicoletti, Paola, Aithal, Guruprasad P., Bjornsson, Einar S., Andrade, Raul J., Sawle, Ashley, Arrese, Marco, Barnhart, Huiman X., Bondon-Guitton, Emmanuelle, Hayashi, Paul H., Bessone, Fernando, Carvajal, Alfonso, Cascorbi, Ingolf, Cirulli, Elizabeth T., Chalasani, Naga, Conforti, Anita, Coulthard, Sally A., Daly, Mark J., Day, Christopher P., Dillon, John F., Fontana, Robert J., Grove, Jane I., Hallberg, Pär, Hernández, Nelia, Ibáñez, Luisa, Kullak-Ublick, Gerd A., Laitinen, Tarja, Larrey, Dominique, Lucena, M. Isabel, Maitland-van der Zee, Anke H., Martin, Jennifer H., Molokhia, Mariam, Pirmohamed, Munir, Powell, Elizabeth E., Qin, Shengying, Serrano, Jose, Stephens, Camilla, Stolz, Andrew, Wadelius, Mia, Watkins, Paul B., Floratos, Aris, Shen, Yufeng, Nelson, Matthew R., Urban, Thomas J., Daly, Ann K.·2017·Gastroenterology
DOI 10.1053/j.gastro.2016.12.016PMC PMC5367948
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2016.12.016

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 51

  1. Gulmez, 2013, Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study, Drug Saf, 36, 135, 10.1007/s40264-012-0013-7 · DOI
  2. Bjornsson, 2015, Risk of drug-induced liver injury from tumor necrosis factor antagonists, Clin Gastroenterol Hepatol, 13, 602, 10.1016/j.cgh.2014.07.062 · DOI · Paper page
  3. Urban, 2014, Genetic basis of drug-induced liver injury: present and future, Semin Liver Dis, 34, 123, 10.1055/s-0034-1375954 · DOI
  4. Kindmark, 2008, Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis, Pharmacogenomics J, 8, 186, 10.1038/sj.tpj.6500458 · DOI
  5. Daly, 2009, HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin, Nat Genet, 41, 816, 10.1038/ng.379 · DOI
  6. Singer, 2010, A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury, Nat Genet, 42, 711, 10.1038/ng.632 · DOI
  7. Lucena, 2011, Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles, Gastroenterology, 141, 338, 10.1053/j.gastro.2011.04.001 · DOI
  8. Spraggs, 2011, HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer, J Clin Oncol, 29, 667, 10.1200/JCO.2010.31.3197 · DOI
  9. Urban, 2012, Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs, Pharmacogenet Genomics, 22, 784, 10.1097/FPC.0b013e3283589a76 · DOI
  10. Bjornsson, 2015, Drug-induced liver injury: an overview over the most critical compounds, Arch Toxicol, 89, 327, 10.1007/s00204-015-1456-2 · DOI
  11. Nicoletti, 2016, HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury, Pharmacogenet Genomics, 26, 218, 10.1097/FPC.0000000000000209 · DOI
  12. Aithal, 2011, Case definition and phenotype standardization in drug-induced liver injury, Clin Pharmacol Ther, 89, 806, 10.1038/clpt.2011.58 · DOI
  13. Fontana, 2009, Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct, Drug Saf, 32, 55, 10.2165/00002018-200932010-00005 · DOI · Paper page
  14. Benichou, 1993, Causality assessment of adverse reactions to drugs—II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge, J Clin Epidemiol, 46, 1331, 10.1016/0895-4356(93)90102-7 · DOI · Paper page
  15. Shen, 2012, Genome-wide association study of serious blistering skin rash caused by drugs, Pharmacogenomics J, 12, 96, 10.1038/tpj.2010.84 · DOI
  16. Tryka, 2014, NCBI's database of genotypes and phenotypes: dbGaP, Nucleic Acids Res, 42, D975, 10.1093/nar/gkt1211 · DOI
  17. Zheng, 2014, HIBAG—HLA genotype imputation with attribute bagging, Pharmacogenomics J, 14, 192, 10.1038/tpj.2013.18 · DOI
  18. Purcell, 2007, PLINK: a tool set for whole-genome association and population-based linkage analyses, Am J Hum Genet, 81, 559, 10.1086/519795 · DOI · Paper page
  19. McCarthy, 2008, Casting a wider net for diabetes susceptibility genes, Nat Genet, 40, 1039, 10.1038/ng0908-1039 · DOI
  20. Haimila, 2013, HLA antigen, allele and haplotype frequencies and their use in virtual panel reactive antigen calculations in the Finnish population, Tissue Antigens, 81, 35, 10.1111/tan.12036 · DOI
  21. Ostrov, 2012, Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire, Proc Natl Acad Sci U S A, 109, 9959, 10.1073/pnas.1207934109 · DOI
  22. Iverson, 2001, Identification of a reactive metabolite of terbinafine: insights into terbinafine-induced hepatotoxicity, Chem Res Toxicol, 14, 175, 10.1021/tx0002029 · DOI
  23. Mizuno, 2010, Terbinafine stimulates the pro-inflammatory responses in human monocytic THP-1 cells through an ERK signaling pathway, Life Sci, 87, 537, 10.1016/j.lfs.2010.08.010 · DOI
  24. Vickers, 1999, Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions, Drug Metab Dispos, 27, 1029, 10.1016/S0090-9556(24)15022-2 · DOI
  25. Miller, 1998, Clinical pharmacokinetics of fibric acid derivatives (fibrates), Clin Pharmacokinet, 34, 155, 10.2165/00003088-199834020-00003 · DOI
  26. Lucena, 2006, Prolonged cholestasis after raloxifene and fenofibrate interaction: a case report, World J Gastroenterol, 12, 5244
  27. Hajdu, 2009, Acute cholestatic hepatitis induced by fenofibrate, J Clin Pharm Ther, 34, 599, 10.1111/j.1365-2710.2009.01029.x · DOI
  28. Skurnik, 2003, Ticlopidine-induced cholestatic hepatitis, Ann Pharmacother, 37, 371, 10.1345/aph.1A406 · DOI
  29. Pizarro, 2001, [Acute hepatitis due to ticlopidine. A report of 12 cases and review of the literature], Rev Neurol, 33, 1014, 10.33588/rn.3311.2001285 · DOI
  30. Kim, 2014, Multiple cytochrome P450 isoforms are involved in the generation of a pharmacologically active thiol metabolite, whereas paraoxonase 1 and carboxylesterase 1 catalyze the formation of a thiol metabolite isomer from ticlopidine, Drug Metab Dispos, 42, 141, 10.1124/dmd.113.053017 · DOI
  31. Yoshikado, 2013, Ticlopidine, a cholestatic liver injury-inducible drug, causes dysfunction of bile formation via diminished biliary secretion of phospholipids: involvement of biliary-excreted glutathione-conjugated ticlopidine metabolites, Mol Pharmacol, 83, 552, 10.1124/mol.112.081752 · DOI
  32. Hirata, 2008, Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study, Pharmacogenomics J, 8, 29, 10.1038/sj.tpj.6500442 · DOI
  33. Ariyoshi, 2010, Enhanced susceptibility of HLA-mediated ticlopidine-induced idiosyncratic hepatotoxicity by CYP2B6 polymorphism in Japanese, Drug Metab Pharmacokinet, 25, 298, 10.2133/dmpk.25.298 · DOI
  34. Raccor, 2012, Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo, Drug Metab Dispos, 40, 54, 10.1124/dmd.111.039347 · DOI
  35. Suen, 2013, Acute liver injury secondary to sertraline, BMJ Case Rep, 2013
  36. Chen, 2014, Sertraline induces endoplasmic reticulum stress in hepatic cells, Toxicology, 322, 78, 10.1016/j.tox.2014.05.007 · DOI
  37. Kurosaki, 2000, HLA-A33/B44/DR6 is highly related to intrahepatic cholestasis induced by tiopronin, Dig Dis Sci, 45, 1103, 10.1023/A:1005585515826 · DOI
  38. Sidney, 2008, HLA class I supertypes: a revised and updated classification, BMC Immunol, 9, 1, 10.1186/1471-2172-9-1 · DOI · Paper page
  39. McCormack, 2011, HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans, N Engl J Med, 364, 1134, 10.1056/NEJMoa1013297 · DOI
  40. Parham, 2016, Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01, Pharmacogenomics J, 16, 180, 10.1038/tpj.2015.40 · DOI
  41. Monshi, 2013, Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury, Hepatology, 57, 727, 10.1002/hep.26077 · DOI
  42. Kim, 2015, Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury, Hepatology, 62, 887, 10.1002/hep.27912 · DOI
  43. Illing, 2012, Immune self-reactivity triggered by drug-modified HLA-peptide repertoire, Nature, 486, 554, 10.1038/nature11147 · DOI
  44. Gamez-Diaz, 2016, The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency, J Allergy Clin Immunol, 137, 223, 10.1016/j.jaci.2015.09.025 · DOI
  45. Cohen, 2015, Primary immunodeficiencies associated with EBV disease, Curr Top Microbiol Immunol, 390, 241
  46. Bogaert, 2016, Genes associated with common variable immunodeficiency: one diagnosis to rule them all?, J Med Genet, 53, 575, 10.1136/jmedgenet-2015-103690 · DOI · Paper page
  47. Levy, 2016, LRBA deficiency with autoimmunity and early onset chronic erosive polyarthritis, Clin Immunol, 168, 88, 10.1016/j.clim.2016.03.006 · DOI
  48. Lo, 2015, Autoimmune disease. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy, Science, 349, 436, 10.1126/science.aaa1663 · DOI
  49. Metushi, 2015, Treatment of PD-1(-/-) mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients, Hepatology, 61, 1332, 10.1002/hep.27549 · DOI
  50. Cadwell, 2016, Cadherin tales: regulation of cadherin function by endocytic membrane trafficking, Traffic, 17, 1262, 10.1111/tra.12448 · DOI
  51. Bjornsson, 2012, Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing, J Hepatol, 56, 374, 10.1016/j.jhep.2011.07.023 · DOI

Cited by

Sorted by citations

Metadata

Authors
Nicoletti, P., Aithal, G. P., Bjornsson, E. S., Andrade, R. J., Sawle, A., Arrese, M., Barnhart, H. X., Bondon-Guitton, E., Hayashi, P. H., Bessone, F., Carvajal, A., Cascorbi, I., Cirulli, E. T., Chalasani, N., Conforti, A., Coulthard, S. A., Daly, M. J., Day, C. P., Dillon, J. F., Fontana, R. J., Grove, J. I., Hallberg, P., Hernández, N., Ibáñez, L., Kullak-Ublick, G. A., Laitinen, T., Larrey, D., Lucena, M. I., Maitland-van der Zee, A. H., Martin, J. H., Molokhia, M., Pirmohamed, M., Powell, E. E., Qin, S., Serrano, J., Stephens, C., Stolz, A., Wadelius, M., Watkins, P. B., Floratos, A., Shen, Y., Nelson, M. R., Urban, T. J., & Daly, A. K.
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2017-04
Volume
152
Issue
5
Pages
1078-1089
ISSN
0016-5085
DOI
10.1053/j.gastro.2016.12.016
PMC
PMC5367948
Cited by
221
References
8
Language
en
Licence
Funders
  • Merck
  • Novartis
  • Hjärt-Lungfonden (20120557)
  • Amgen
  • Pfizer
  • GlaxoSmithKline
  • Vetenskapsrådet (521-2011-2440)
  • Instituto de Salud Carlos III
  • Guy's and St Thomas' NHS Foundation Trust
  • Svenska Läkaresällskapet (2008-21619)
  • Indiana University (U01DK065193)
  • National Institute for Health and Care Research
  • Roche
  • King's College London (EC08/00250)
  • Sanofi
  • University of Southern California (U01-DK100928)
  • Duke University (U01-DK065201)
  • University of Nottingham
  • School of Medicine, CHA University (UL1 RR024986, UL1 RR025761, UL1 TR001111)
  • Comisión Nacional de Investigación Científica y Tecnológica (PIA/Basal PFB12)
  • Daiichi-Sankyo
  • University of Texas Southwestern Medical Center (U01-DK083027)
  • University of North Carolina (U01-DK065184)
  • University of Michigan (U01-DK065211)
  • University of Connecticut (U01-DK065238)
  • University of North Carolina Wilmington
  • Takeda Pharmaceutical Company
  • Wellcome Trust
  • Manchester Biomedical Research Centre
  • Mayo Clinic (U01-DK083020)
  • Abbott Laboratories
  • European Regional Development Fund (FIS PI12/00378, P10-CTS-6470)
  • National Institutes of Health (U01-DK065176)
  • National Institute of Diabetes and Digestive and Kidney Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review